MUSK and myasthenia gravis: The same group (96) also reported that tacrolimus, an immunosuppressant for AChR+ MG, inhibited Th1 and Th17 responses, and reduced Treg frequencies of in vitro cultured peripheral blood mononuclear cells (PBMCs) from MuSK+ MG patients.